Annual US sales of the J&J vaginal cream and suppository are $90 million.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has obtained final US Food and Drug Administration (FDA) approval for the company's Miconazole Nitrate Vaginal Cream and Suppository, an over-the-counter generic version Johnson & Johnson's (NYSE: JNJ) Monistat, Combination Pack. Perrigo will begin shipments immediately.
Brand Monistat has annual US sales of $90 million.
Perrigo was the first to file an Abbreviated New Drug Application (ANDA) with Paragraph IV certification with the FDA, and subsequently won patent litigation filed by Johnson & Johnson.
Perrigo's share price rose 0.8% on the TASE today, and rose 2.4% at the opening on Nasdaq to $58.85.
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010